Exelixis Inc (EXEL)
What changed in recent filings
- United States segment 89% → 92%Sep 30, 2024 → Jun 30, 2026
What changed in recent SEC filings — factual, not a buy/sell recommendation.
Company overview
Exelixis. A biotech targeting kidney- and liver-cancer markets with the oncology drug cabozantinib.
What is the Biotech & Health sector?
Pharma, biotech, and medical devices. Driven by trial-result events.
Exelixis Inc is classified under the Biotech & Health sector. See peers below.
Exelixis Inc key financials
Based on SEC filings · as of Jul 3, 2026
Tap a metric name to see its meaning in the glossary.
Exelixis Inc vs Biotech & Health sector benchmark
Median of 35 representative sector stocks · SEC filings · factual comparison (not advice)
A simple comparison to the sector benchmark. Higher or lower doesn’t mean good/bad or buy/sell.
EXEL segment revenue mix trend
Quarterly change in segment revenue share · verified from SEC filings
ETFs holding Exelixis Inc
Per SEC N-PORT · 2026-06-30 · by weight · factual
EXEL on Stocklore
- Revenue by segment — segment weights verified from SEC filings, YoY changes, growth drivers and concentration
- Financials & earnings quality — 6 metrics (FCF conversion, ROIC, net debt, etc.) to gauge profit quality
- 13F institutional holdings — holdings and weight changes of major institutions (45-day delay)
- Sector-relative metrics — Valuation and growth compared with the Biotech & Health average
Peers · Biotech & Health
EXEL FAQ
What is Exelixis Inc (EXEL)?
Exelixis. A biotech targeting kidney- and liver-cancer markets with the oncology drug cabozantinib.
What sector is Exelixis Inc in?
Exelixis Inc is classified under Biotech & Health. Pharma, biotech, and medical devices. Driven by trial-result events.
What are Exelixis Inc's key financials?
As of Jul 3, 2026 in SEC filings: Revenue growth (YoY) 9.2%, Operating margin 39.5%, Net margin 35.3%, ROE 36.2%. Definitions and interpretation are available on Stocklore.
Where can I analyze Exelixis Inc (EXEL) stock?
On Stocklore you can see EXEL's financials & earnings quality, 13F institutional holdings, and sector-relative metrics in one place. This page is for information and tools — not a buy/sell recommendation.
Data sources: SEC EDGAR (financials & filings), 13F (institutional holdings, as of quarter-end), market data. This page is for information and analysis tools — it does not recommend buying or selling any security. Investment decisions and responsibility are your own.